[et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”]

Neurodivergent Medication Survey

[/et_pb_text][et_pb_text _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”]

The Health and Social Care Committee of the UK Parliament held an inquiry on January 16, 2024, focusing on the potential of community pharmacies to provide diagnostic and treatment services. The session included oral evidence from individuals such as Deborah Evans, Clinic Director at Remedi Health, and William Pett, Head of Policy at Healthwatch England. Topics discussed included the role of community pharmacies in patient care, the Pharmacy First service allowing pharmacists to supply certain prescription-only medicines, and concerns about the feasibility of NHS plans to recruit more pharmacists and technicians to meet growing demand. The inquiry aimed to address challenges in the pharmacy sector across hospitals, the community, and general practice.

More than 600,000 people are affected by Epilepsy in the UK with some being forced to start rationing their meds. A national shortage of epilepsy medication is putting patients’ safety at risk, consultants have said. 


The supply disruption of ADHD meds is caused by a combination of manufacturing issues and an increased global demand. 


This is obviously a cause for concern.



AnnaKennedyonline have created two surveys one tailored for neurodiverse individuals who rely on medication to meet their support needs and another for this how provide care support. 

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][/et_pb_code][/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][/et_pb_code][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”]

Above are two questionnaires: one tailored for neurodiverse individuals who rely on medication to meet their support needs and another for this how provide care support.


Our objective is to unveil and document the ramifications of the shortage of medication utilised by neurodiverse adults. We aspire to evaluate the impact of these shortages on individuals and proffer suggestions on how to enhance the situation.


Our aim is to extend assistance to the charity’s members and facilitate healthcare providers in addressing this persisting issue. Additionally, we seek to harness our capacity to gather feedback for the pharmacy industry and encourage collaborative partnerships to ensure that this pivotal matter garners the attention it rightfully warrants.

[/et_pb_text][et_pb_image src=”https://www.annakennedyonline.com/wp-content/uploads/2023/03/AKOLOGO-1.png.webp” title_text=”AKOLOGO-1.png” align=”center” _builder_version=”4.24.0″ _module_preset=”default” max_width=”50%” global_colors_info=”{}”][/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section]

Leave a Reply

Your email address will not be published. Required fields are marked *